Safety and Performance of MIRASOL® PRT Treated Platelet Transfusion Products

Early Phase 1CompletedNCT00263809

Terumo BCTbio118 enrolled

Overview

The primary objective of the study is to measure platelet corrected count increments and the incidence of serious adverse events (SAE). The primary endpoint is the platelet corrected count increment measured 1-hour post transfusion in response to the infusion of platelet concentrates treated with the Mirasol PRT System device (test product) versus untreated (reference product).

The objective of the study is to determine if the MIRASOL Pathogen Reduction Technology (PRT) System for Platelets device performs safely and maintains adequate platelet performance in a clinical setting. This will be achieved by comparing the platelet corrected count increment measured 1 hour post transfusion and the incidence of serious adverse events in response to the infusion of platelet concentrates treated with the device (test product) versus untreated (reference product) in thrombocytopenic subjects requiring platelet transfusions. The performance, safety, and tolerability profile of the device will be further assessed by monitoring and comparing the incidence of discontinuations due to adverse events in relation to platelet transfusion up to 4 weeks after transfusion, including the incidence of transfusion associated infections, and the number and time between transfusions.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

118

Conditions

Thrombocytopenia

Interventions

Pathogen Reduction TechnologyDEVICE

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female of age of 16 years or older * Women of Child Bearing Potential not pregnant * Subject must have signed and dated the Informed Consent form * Hospitalized, thrombocytopenic subjects and expected to receive at least two platelets transfusion Exclusion Criteria: * History of any hypersensitivity reaction to riboflavin or metabolites * History of refractoriness to platelet transfusions * Positive lymphocytotoxic antibody test * Active bleeding * Splenomegaly * Acute or chronic Disseminated Intravascular Coagulation * History or diagnosis of Immune/Idiopathic Thrombocytopenic Purpura, Thrombotic Thrombocytopenia Purpura, or Haemolytic Uremic Syndrome * History or diagnosis of an autoimmune disease affecting haemostasis * History of solid organ transplants * Evidence of occlusive venous disease * Clinical signs of infection at the time of inclusion * Pregnant or lactating females * Chronic alcohol misuse * Use of prohibited medications

Locations (10)

Centre Hospitalier Universitaire Jean Minjoz

Besançon, France

EFS Bourgogne - Franche-Comté

Besançon, France

EFS Aquitaine

Bordeaux, France

Centre Hospitalier Univesrsitaire A Michallon

Outcomes

Primary Outcomes

The platelet corrected count increment measured 1 hour post transfusion.

Secondary Outcomes

The platelet corrected count increment measured 24 hours post-transfusion.

The number of days between platelet transfusions during the period of the study.

The number of platelet transfusions per subject.

The number of platelets infused per subject.

The number of platelets used.

The frequency of refractoriness to platelet transfusion.

In case of refractoriness, the evidence for neoantigen immunization against test product.

The number of red blood cell transfusions during the study period.

The incidence of serious adverse events in relation to platelet transfusions.

The incidence of any adverse events in relation to platelet transfusions.

The occurrence of bleeding episodes.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.